Sugi Predict

Sugi Predict / Compounds / SCHEMBL773365

SCHEMBL773365

SCHEMBL773365

CN1C(=S)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12

nearest known ligand 0.85

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 20/20 0.85
▸ PDE2A O00408 3/20 0.80
▸ PDE8A O60658 3/20 0.80
▸ PDE5A O76074 3/20 0.80
▸ PDE3B Q13370 3/20 0.80
▸ PDE11A Q9HCR9 3/20 0.80
▸ PDE7B Q9NP56 3/20 0.80
▸ PDE10A Q9Y233 3/20 0.80
▸ PDE9A O76083 2/20 0.80
▸ PDE1B Q01064 1/20 0.80
▸ PDE4B Q07343 1/20 0.80
▸ PDE4C Q08493 1/20 0.80
▸ PDE4D Q08499 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lenrispodun SCHEMBL18211963 0.92 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL10201342 0.92 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL16324627 0.92 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL29415040 0.92 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL18771113 0.92 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL775307 0.91 PDE4A (0.71) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL20341393 0.90 PDE4A (0.97) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL16576765 0.89 PDE4A (0.82) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL773887 0.89 PDE4A (0.84) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL23610593 0.89 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11291666-B2 Uses INTRA-CELLULAR THERAPIES, INC. (US) 2022-04-05 — — US disclosed
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors INTRA-CELLULAR THERAPIES, INC. (US) 2021-11-09 — — US disclosed
US-20210213018-A1 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2021-07-15 — — US disclosed
US-20200289518-A1 METHOD FOR TREATING BRAIN OR NERVE INJURY CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-09-17 — — US disclosed
US-20190275046-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-12 — — US disclosed
US-10398698-B2 Uses INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-03 — — US disclosed
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods INTRA-CELLULAR THERAPIES, INC. (US) 2019-05-14 — — US disclosed
US-20180177782-A9 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2018-06-28 — — US disclosed
US-20180177782-A9 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2018-06-28 — — US disclosed
US-20180000825-A1 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2018-01-04 — — US disclosed
US-8633180-B2 Organic compounds INTRA-CELLULAR THERAPIES, INC. (US) 2014-01-21 — — US disclosed
US-20140011783-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2014-01-09 — — US disclosed
US-20140011783-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2014-01-09 — — US disclosed
US-20140011783-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2014-01-09 — — US disclosed
US-20120071450-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2012-03-22 — — US disclosed
US-20120071450-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2012-03-22 — — US disclosed
US-20120071450-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2012-03-22 — — US disclosed
EP-2358723-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2011-08-24 — — EP disclosed
WO-2010065151-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 — — WO disclosed
WO-2010065151-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180000825-A1 NOVEL USES PDE2A, PDE5A, PDE3A PDE4A 6/4885PDE2A 1/4885PDE8A 48/4885
US-20200289518-A1 METHOD FOR TREATING BRAIN OR NERVE INJURY GAP43, NGF, CHAT PDE4A 236/4885PDE2A 475/4885PDE8A 2134/4885
US-10398698-B2 Uses PDE5A, PDE2A, PDE3A PDE4A 6/4885PDE2A 2/4885PDE8A 59/4885
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods PDE5A, PDE3A, PDE2A PDE4A 8/4885PDE2A 3/4885PDE8A 178/4885
US-20210213018-A1 NOVEL USES PDE2A, PDE4A, PDE1A PDE4A 2/4885PDE2A 1/4885PDE8A 18/4885
US-20140011783-A1 ORGANIC COMPOUNDS TYMS, TPMT, THPO PDE4A 1155/4885PDE2A 1793/4885PDE8A 1775/4885
US-11291666-B2 Uses PDE2A, PDE3A, PDE5A PDE4A 4/4885PDE2A 1/4885PDE8A 22/4885
US-20120071450-A1 ORGANIC COMPOUNDS TYMS, TPMT, THPO PDE4A 1155/4885PDE2A 1793/4885PDE8A 1775/4885
US-20190275046-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A PDE4A 9/4885PDE2A 2/4885PDE8A 303/4885
US-20180177782-A9 NOVEL USES PDE2A, PDE5A, PDE3A PDE4A 6/4885PDE2A 1/4885PDE8A 48/4885
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors PDE5A, ECE1, PDE3A PDE4A 10/4885PDE2A 4/4885PDE8A 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.